在低风险多细胞血病中进行罗佩基干扰素二期随机研究:5年药物存活率和疗效结果
Tiziano Barbui1, Alessandra Carobbio2, Valerio De Stefano3
1FROM, Fondazione Per La Ricerca Ospedale Di Bergamo ETS, Papa Giovanni XXIII Hospital, 24127, Bergamo, Italy. tbarbui@fondazionefrom.it.
Annals of hematology
|December 7, 2023
概括
对于低风险的真多细胞血症,Ropeg干扰素α-2b (Ropeg) 比瘤切除更有效,维持血和减少瘤切除的需要. 长期使用Ropeg显示持续的疗效和药物生存的高概率.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 多细胞血病真 (PV) 是一种骨髓增殖性瘤,其特征是血升高.
- 低风险PV的标准治疗通常涉及治疗性瘤切除,以维持血红素水平.
- 罗佩干扰素α-2b (Ropeg) 是一种替代治疗选择,在管理PV方面具有潜在的益处.
研究的目的:
- 评估Ropeg在低风险多细胞真血病患者的长期疗效,安全性,坚持性和耐受性.
- 为了比较Ropeg和单纯瘤手术治疗之间的药物存活率.
- 为了确定影响治疗失败的因素,并为最佳的Ropeg剂量策略提供信息.
主要方法:
- 分析药物存活率作为有效性,安全性,坚持性和耐受性的替代品,长达5年的时间.
- 由于缺乏反应或不良事件导致的治疗中止率的比较,在Ropeg和仅进行瘤手术的组之间.
- 在继续Ropeg治疗的患者中对初级复合终点维持的评估.
主要成果:
- 罗佩格的疗效优于单纯的瘤手术,在前两年中,药物停用率较低 (33%对70%).
- 对于Ropeg响应者的药物生存概率在平均3.15年后为59%.
- 在接受Ropeg治疗的患者中,超过94%的患者在3-5年内维持了初级复合终点,其中60%的患者没有进行瘤手术.
结论:
- 罗佩格是低风险真多细胞血症的有效长期治疗方法,可提供持续的血红素控制并减少瘤切除的需要.
- 早期启动Ropeg,可能增加剂量,可能是有益的,特别是在前六个月内需要高瘤手术的患者中.
- 高的药物存活率和持续的疗效表明Ropeg是管理真多细胞血症的有价值的治疗选择.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...


